LAUSR

TPS1100Background: There is no clear standard of care to address the management of refractory CNS metastases in HER2+ MBC. The ongoing study (NCT03417544) is evaluating the efficacy of the combination of Atezo with P and high-dose H for the treatment of CNS metastases in patients (pts) with HER2-positive MBC. Methods: This is a phase II, single arm, multi-center trial assessing the efficacy of Atezo with Pertuzumab plus high-dose H for the treatment of CNS metastases in HER2+ MBC. Participants will receive Atezo [1200mg every 3 weeks (q3w)], P (840-mg loading dose, then 420mg q3w), and high-dose H (6 mg/kg weekly for 24 weeks, and then q3w). Eligibility Criteria include pts with HER2+ MBC, at least one measurable CNS metastasis (≥10 mm), unequivocal evidence of new and/or progressive CNS metastases, and left ventricular ejection fraction (LVEF) ≥ 50%. Exclusion criteria include CNS complications for whom urgent neurosurgical intervention is needed; known leptomeningeal/brainstem metastases; and treatment ...